2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Multicolor, Cell-Impermeable, and High Affinity BACE1 Inhibitor Probes Enable Superior Endogenous Staining and Imaging of Single Molecules

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The prevailing but not undisputed amyloid cascade hypothesis places the β-site of APP cleaving enzyme 1 (BACE1) center stage in Alzheimer′s Disease pathogenesis. Here, we investigated functional properties of BACE1 with novel tag- and antibody-free labeling tools, which are conjugates of the BACE1-inhibitor IV (also referred to as C3) linked to different impermeable Alexa Fluor dyes. We show that these fluorescent small molecules bind specifically to BACE1, with a 1:1 labeling stoichiometry at their orthosteric site. This is a crucial property especially for single-molecule and super-resolution microscopy approaches, allowing characterization of the dyes′ labeling capabilities in overexpressing cell systems and in native neuronal tissue. With multiple colors at hand, we evaluated BACE1-multimerization by Förster resonance energy transfer (FRET) acceptor-photobleaching and single-particle imaging of native BACE1. In summary, our novel fluorescent inhibitors, termed Alexa-C3, offer unprecedented insights into protein–protein interactions and diffusion behavior of BACE1 down to the single molecule level.

          Related collections

          Most cited references67

          • Record: found
          • Abstract: found
          • Article: not found

          NIH Image to ImageJ: 25 years of image analysis

          For the past twenty five years the NIH family of imaging software, NIH Image and ImageJ have been pioneers as open tools for scientific image analysis. We discuss the origins, challenges and solutions of these two programs, and how their history can serve to advise and inform other software projects.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            The amyloid hypothesis of Alzheimer's disease at 25 years

            Abstract Despite continuing debate about the amyloid β‐protein (or Aβ hypothesis, new lines of evidence from laboratories and clinics worldwide support the concept that an imbalance between production and clearance of Aβ42 and related Aβ peptides is a very early, often initiating factor in Alzheimer's disease (AD). Confirmation that presenilin is the catalytic site of γ‐secretase has provided a linchpin: all dominant mutations causing early‐onset AD occur either in the substrate (amyloid precursor protein, APP) or the protease (presenilin) of the reaction that generates Aβ. Duplication of the wild‐type APP gene in Down's syndrome leads to Aβ deposits in the teens, followed by microgliosis, astrocytosis, and neurofibrillary tangles typical of AD. Apolipoprotein E4, which predisposes to AD in > 40% of cases, has been found to impair Aβ clearance from the brain. Soluble oligomers of Aβ42 isolated from AD patients' brains can decrease synapse number, inhibit long‐term potentiation, and enhance long‐term synaptic depression in rodent hippocampus, and injecting them into healthy rats impairs memory. The human oligomers also induce hyperphosphorylation of tau at AD‐relevant epitopes and cause neuritic dystrophy in cultured neurons. Crossing human APP with human tau transgenic mice enhances tau‐positive neurotoxicity. In humans, new studies show that low cerebrospinal fluid (CSF) Aβ42 and amyloid‐PET positivity precede other AD manifestations by many years. Most importantly, recent trials of three different Aβ antibodies (solanezumab, crenezumab, and aducanumab) have suggested a slowing of cognitive decline in post hoc analyses of mild AD subjects. Although many factors contribute to AD pathogenesis, Aβ dyshomeostasis has emerged as the most extensively validated and compelling therapeutic target.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Alzheimer's disease: the amyloid cascade hypothesis

                Bookmark

                Author and article information

                Journal
                J Med Chem
                J Med Chem
                jm
                jmcmar
                Journal of Medicinal Chemistry
                American Chemical Society
                0022-2623
                1520-4804
                06 June 2024
                27 June 2024
                : 67
                : 12
                : 10152-10167
                Affiliations
                []Institut für Physiologie und Pathophysiologie, Friedrich-Alexander-Universität Erlangen-Nürnberg , Erlangen 91054, Germany
                []Department of Chemical Biology, Max Planck Institute for Medical Research , Heidelberg 69120, Germany
                [§ ]Leibniz-Forschungsinstitut für Molekulare Pharmakologie , Berlin 13125, Germany
                []Université Côte d’Azur , CNRS, INSERM, iBV, Nice 06108, Cedex 2, France
                []Laboratories of Excellence, Ion Channel Science and Therapeutics , Nice 06108, Cedex 2, France
                Author notes
                Author information
                https://orcid.org/0009-0002-9101-7491
                https://orcid.org/0000-0001-8137-4853
                https://orcid.org/0000-0003-0501-2193
                https://orcid.org/0000-0002-6414-8923
                https://orcid.org/0000-0003-3084-6595
                Article
                10.1021/acs.jmedchem.4c00339
                11215771
                38842406
                ae81af2d-7cb3-4536-9d97-76a9a739013e
                © 2024 The Authors. Published by American Chemical Society

                Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained ( https://creativecommons.org/licenses/by/4.0/).

                History
                : 07 February 2024
                : 28 May 2024
                : 10 May 2024
                Funding
                Funded by: H2020 European Research Council, doi 10.13039/100010663;
                Award ID: 101042046
                Funded by: Universitätsbund Erlangen-Nürnberg, doi 10.13039/501100007947;
                Award ID: NA
                Funded by: Agence Nationale de la Recherche, doi 10.13039/501100001665;
                Award ID: ANR-11-LABX-0015-01
                Funded by: Deutsche Forschungsgemeinschaft, doi 10.13039/501100001659;
                Award ID: HU 2358/1-1
                Categories
                Article
                Custom metadata
                jm4c00339
                jm4c00339

                Pharmaceutical chemistry
                Pharmaceutical chemistry

                Comments

                Comment on this article